氨酸向疟疾激酶PfCLK3的共价抑制剂Pf
Skye B Brettell1, Gillian Cann2, Abbey Begen2
1School of Chemistry, The Advanced Research Centre, University of Glasgow 11 Chapel Lane Glasgow G11 6EW UK andrew.jamieson.2@glasgow.ac.uk.
RSC medicinal chemistry
|June 16, 2025
概括
研究人员开发了新的抗疟疾药物,针对Plasmodium falciparum CLK3 (PfCLK3) 激酶中的必需氨酸残留物. 这些新型的氨酸向性共价抑制剂为克服疟疾治疗中抗药性提供了有希望的策略.
科学领域:
- 药用化学 医学化学
- 寄生虫学的寄生虫学
- 药物发现 药物发现 药物发现
背景情况:
- 疟疾仍然是一个重大的全球健康威胁,因药物耐药性增加而加剧.
- 激酶抑制是一种有前途的治疗策略,可以对抗疟疾寄生虫.
- 之前开发的TCMDC-135051 (1) 已经显示出对Plasmodium falciparum CLK3 (PfCLK3) 的强烈抑制.
研究的目的:
- 开发新型抗疟疾药物,绕过与氨酸向性共价抑制剂相关的抗性机制.
- 探索针对 PfCLK3.3 的必需激酶催化氨酸残留物 (Lys394) 的向.
- 设计和合成TCMDC-135051 (1) 的类似物,这些类似物可对 Lys394.4 产生共价作用.
主要方法:
- 基于结构的药物设计被用来创建新的类似物.
- 基于甲的弹头被纳入了抑制器结构.
- 用蛋白质质谱法证实了Lys394.4的共价结合.
主要成果:
- 合成了四种新型化合物 (4,5,8,9),并证明它们与PfCLK3.3的Lys394具有共价结合.
- 这些化合物对复合PfCLK3.3表现出高强度.
- 类似物显示出有前途的杀虫活性和有利的细胞毒性概况.
结论:
- 开发的分子代表了首次报告的氨酸向性对疟疾的共价抑制剂.
- 这种新的策略为克服抗疟疾药物发现中的抗药性机制提供了一个潜在的方法.
- 这些发现为开发下一代抗疟疾疗法铺平了道路.
相关概念视频
The JAK-STAT Signaling Pathway
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Anthelminthic Agents
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...


